SPC 839 (compound 10) is an orally active inhibitor of AP-1 and NF-kB mediated transcriptional activation with IC50 of 0.008 μM.
SPC 839 (compound 10) (30 mg/kg, p.o., 21 days) shows significant activity in adjuvant-induced arthritis rat model, reducing uninjected foot swelling by 65%[1].
References:
[1]. Moort S S Palanki, et al. The design and synthesis of novel orally active inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. SAR of in vitro and in vivo studies. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4077-80.